-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Type 2 diabetes (T2DM) is a progressive disease characterized by the deterioration and eventual loss of pancreatic β-cell function, leading to insufficient insulin secretion and chronic hyperglycemia.
Diabetes In 2019, there were 463 million people with diabetes worldwide, of which China accounted for 116.
Efficacy and safety of LY2963016 insulin glargine (LY IGlar) and insulin glargine (Lantus®; IGlar) combined with oral hypoglycemic drugs (OAM) in the treatment of T2DM
This is an open-label Phase III trial conducted in China.
HbA1c changes in the two groups
HbA1c changes in the two groupsCompared with the baseline, the glycosylated hemoglobin (HbA1c) of patients in the LY IGlar group (n=359) and IGlar group (n=177) had a similar and significant decrease (P<0.
From baseline to 24 weeks, LY IGlar was not inferior to IGlar in HbA1c changes (-1.
Proportion of patients with HbA1c falling to different levels in the two groups
Proportion of patients with HbA1c falling to different levels in the two groupsTherefore, this study shows that LY IGlar and IGlar are equivalent in terms of the primary endpoint .
The primary endpoint is convenient, LY IGlar and IGlar have equivalent hypoglycemia
In summary, on the basis of oral hypoglycemic drugs, LY IGIar or IGIar once a day can provide effective and similar blood glucose control effects for adult patients with T2DM , and have similar safety.
On the basis of oral hypoglycemic drugs, using LY IGIar or IGIar once a day can provide effective and similar blood glucose control effects for adult patients with T2DM
Original source:
Original source:Feng Wenhuan,Chen Wei,Jiang Shan et al.
org/10.
1111/dom.
14392" target="_blank" rel="noopener">Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus?) In Chinese adults with type 2 diabetes mellitus: A Phase III, randomised, open-label, controlled tria
in this message
